echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > "New Crown" Hot Spot This Chinese pharmaceutical company faces a class action!

    "New Crown" Hot Spot This Chinese pharmaceutical company faces a class action!

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The lawsuit accuses Sorrento Therapeutics of violating the U.S. Securities Exchange Act, and Dr. Henry Ji, the company's founder and chief executive, announced on May 15th that he had made a major breakthrough and had found an antibody that 100 percent effectively blocks and removes the new coronavirus. On May 15,
    , Sorrento Therapeutics said its scientists believe dissonant has found the first antibody for the new coronavirus, STI-1499, which will be used in a cocktail therapy called COVI-SHIELD.
    followed, Sorrento Therapeutics shares soared.
    the lawsuit said the company's shares rose sharply on the day (May 15) from $2.62 to $6.76 a share.
    rose as high as $10 on the next trading day (May 18), but quickly fell to $4.62 (close on June 12).
    the lawsuit alleges that Sorrento Therapeutics concealed the following facts: (i) Sorrento exaggerated the prospect that STI-1499 antibodies were used to completely suppress the new coronavirus;
    Sorrento Therapeutics was founded in 2006 and is one of the founders of Dr. Ji Hongjun, a Chinese," and was the company's founding chief scientist.
    another founder, Antonius Schuh, is the company's chairman and CEO.
    2011, Antonius Schuh chose to leave Sorrento, where ji Hongjun, one of its founders, took over as company's chief executive.
    before starting Sorrento, Ji Hongjun had been in the start-up between the two companies for many years.
    graduated from HaiFudan University with a degree in biochemistry, and came to the University of Minnesota in the 1980s to study for a Ph.D. in animal physiology.
    after ji Hongjun began his biopharmaceutical career.
    its co-founder, Stratagene Corporation, was acquired by Agilent in 2001.
    , mr. Ji served as vice president and president of Combi Matrix and BioVintage before starting Sorrento, but neither was able to last long.
    finally ji Hongjun is back on the road to entrepreneurship.
    this time he started his business, and he has been here for 14 years.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.